<p>&nbsp;</p> <p align="justify">With 14,383 jobs, the <a title="" style="color: rgb(224, 32, 32);" href="https://www.aderly.com/pharmaceutique_biotech/index,p,100044,EN.jsp" target="_blank">pharmaceutical industry in the Rh&#244;ne-Alpes region&nbsp; </a>has confirmed its rank as Number 2 in France, after the Paris region (24,221 jobs). Rh&#244;ne County alone accounts for three-fourths of employment in the region, with 10,786 jobs, of which 3,400 are at <a title="" style="color: rgb(224, 32, 32);" href="https://www.aderly.com/france-pharmaceutique/entreprise-lyon-sanofi-aventis-pharmaceutique,p,130,EN.jsp" target="_blank">Sanofi</a> in Marcy-l’Etoile, near Lyon. <strong>The workforce at pharmaceutical companies has grown by 34% over the past 20 years, i.e. 3,675 additional jobs</strong>, whereas the Paris region has dropped by 37%, i.e. 14,000 fewer jobs over the same period. <br>According to Antonio Sedeno, who just completed a report for INSEE national statistics agency, entitled, <em>L’Industrie Rh&#244;ne-alpine, entre d&#233;sindustrialisation et mutations industrielles</em> (Industry in the Rhone-Alpes region, between de-industrialization and industrial transformation), the difference between the region and the capital can be explained in part by the economic history of Rh&#244;ne-Alpes and its ties with the chemical industry, especially in the Lyon area, and by the <strong>presence of the competitiveness cluster <a title="" style="color: rgb(224, 32, 32);" href="https://www.aderly.com/lyon-biopole-pole-centre-recherche-scientifique/index,p,98,EN.jsp" target="_blank">Lyonbiop&#244;le</a>, ranked among the top 20 performing clusters in 2012</strong>. <br></p> <p align="justify">Since its creation in 2005, Lyonbiop&#244;le has brought together four major corporations, 102 small, medium and large companies, along with 20 research and training organizations. The cluster has produced 119 R&amp;D projects for a total investment of &#8364;588 million. Focused on the fight against infectious diseases in humans and animals and against cancer of all types, the Lyon cluster will soon benefit from the <strong>Accinov</strong> platform in 2013 and the new technological research institute (IRT) <strong>Bioaster</strong>, to accelerate its development. <br></p> <p align="justify"><br></p>